[1]
|
Meng, Z., Moroishi, T., Guan, K., et al. (2016) Mechanisms of Hippo Pathway Regulation. Genes & Development, 30, 1-17. https://doi.org/10.1101/gad.274027.115
|
[2]
|
Zanconato, F., Cordenonsi, M. and Piccolo, S. (2016) YAP/TAZ at the Roots of Cancer. Cancer Cell, 29, 783-803.
https://doi.org/10.1016/j.ccell.2016.05.005
|
[3]
|
Ma, S., Meng, Z., Chen, R., et al. (2019) The Hippo Pathway: Biology and Pathophysiology. Annual Review of Biochemistry, 88, 577-604. https://doi.org/10.1146/annurev-biochem-013118-111829
|
[4]
|
Harbeck, N. and Gnant, M.L. (2017) Breast Cancer. The Lancet, 389, 1134-1150.
https://doi.org/10.1016/S0140-6736(16)31891-8
|
[5]
|
Chan, E., Nousiainen, M., Chalamalasetty, R., et al. (2005) The Ste20-Like Kinase Mst2 Activates the Human Large Tumor Suppressor Kinase Lats1. Oncogene, 24, 2076-2086. https://doi.org/10.1038/sj.onc.1208445
|
[6]
|
Varelas, X. (2014) The Hippo Pathway Effectors TAZ and YAP in Development, Homeostasis and Disease. Development, 141, 1614-1626. https://doi.org/10.1242/dev.102376
|
[7]
|
Yu, F., Zhao, B., Panupinthu, N., et al. (2012) Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling. Cell, 150, 780-791. https://doi.org/10.1016/j.cell.2012.06.037
|
[8]
|
Hong, W. and Guan, K. (2012) The YAP and TAZ Transcription Co-Activators: Key Downstream Effectors of the Mammalian Hippo Pathway. Seminars in Cell & Developmental Biology, 23, 785-793.
https://doi.org/10.1016/j.semcdb.2012.05.004
|
[9]
|
Vici, P., Ercolani, C., Di Benedetto, A., et al. (2016) Topographic Expression of the Hippo Transducers TAZ and YAP in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. Journal of Experimental & Clinical Cancer Research, 35, Article No. 62. https://doi.org/10.1186/s13046-016-0338-7
|
[10]
|
Khanal, P., Yeung, B., Zhao, Y., et al. (2019) Identification of Prolyl Isomerase Pin1 as a Novel Positive Regulator of YAP/TAZ in Breast Cancer Cells. Scientific Reports, 9, Article No. 6394. https://doi.org/10.1038/s41598-019-42767-w
|
[11]
|
Kushner, M., Ory, V., Graham, G., et al. (2020) Loss of ANCO1 Repression at AIB1/YAP Targets Drives Breast Cancer Progression. EMBO Reports, 21, e48741. https://doi.org/10.15252/embr.201948741
|
[12]
|
Gong, C., Bauvy, C., Tonelli, G., et al. (2013) Beclin 1 and Autophagy Are Required for the Tumorigenicity of Breast Cancer Stem-Like/Progenitor Cells. Oncogene, 32, 2261-72, 72e.1-11. https://doi.org/10.1038/onc.2012.252
|
[13]
|
Mathew, R. and White, E. (2011) Autophagy in Tumorigenesis and Energy Metabolism: Friend by Day, Foe by Night. Current Opinion in Genetics and Development, 21, 113-119. https://doi.org/10.1016/j.gde.2010.12.008
|
[14]
|
Song, Q., Mao, B., Cheng, J., et al. (2015) YAP Enhances Autophagic Flux to Promote Breast Cancer Cell Survival in Response to Nutrient Deprivation. PLoS ONE, 10, e0120790. https://doi.org/10.1371/journal.pone.0120790
|
[15]
|
Wei, H., Wei, S., Gan, B., et al. (2011) Suppression of Autophagy by FIP200 Deletion Inhibits Mammary Tumorigenesis. Genes & Development, 25, 1510-1527. https://doi.org/10.1101/gad.2051011
|
[16]
|
Chen, W., Bai, Y., Patel, C., et al. (2019) Autophagy Promotes Triple Negative Breast Cancer Metastasis via YAP Nuclear Localization. Biochemical and Biophysical Research Communications, 520, 263-268.
https://doi.org/10.1016/j.bbrc.2019.09.133
|
[17]
|
Wang, Z., Wu, Y., Wang, H., et al. (2014) Interplay of Mevalonate and Hippo Pathways Regulates RHAMM Transcription via YAP to Modulate Breast Cancer Cell Motility. Proceedings of the National Academy of Sciences of the United States of America, 111, E89-E98. https://doi.org/10.1073/pnas.1319190110
|
[18]
|
Hiemer, S., Szymaniak, A. and Varelas, X. (2014) The Transcriptional Regulators TAZ and YAP Direct Transforming Growth Factor β-Induced Tumorigenic Phenotypes in Breast Cancer Cells. Journal of Biological Chemistry, 289, 13461-13474. https://doi.org/10.1074/jbc.M113.529115
|
[19]
|
Zhao, B., Wei, X., Li, W., et al. (2007) Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes & Development, 21, 2747-2761.
https://doi.org/10.1101/gad.1602907
|
[20]
|
Hanahan, D. and Weinberg, R. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[21]
|
Weigelt, B., Peterse, J. and Van’t Veer, L. (2005) Breast Cancer Metastasis: Markers and Models. Nature Reviews. Cancer, 5, 591-602. https://doi.org/10.1038/nrc1670
|
[22]
|
Tan, B., Yang, M., Singh, S., et al. (2019) LncRNA NORAD Is Repressed by the YAP Pathway and Suppresses Lung and Breast Cancer Metastasis by Sequestering S100P. Oncogene, 38, 5612-5626.
https://doi.org/10.1038/s41388-019-0812-8
|
[23]
|
He, X., Lee, B., Jiang, Y., et al. (2016) Cell-ECM Interactions in Tumor Invasion. Advances in Experimental Medicine and Biology, 936, 73-91. https://doi.org/10.1007/978-3-319-42023-3_4
|
[24]
|
Shen, J., Cao, B., Wang, Y., et al. (2018) Hippo Component YAP Promotes Focal Adhesion and Tumour Aggressiveness via Transcriptionally Activating THBS1/FAK Signalling in Breast Cancer. Journal of Experimental & Clinical Cancer Research, 37, 175. https://doi.org/10.1186/s13046-018-0850-z
|
[25]
|
Hu, C., Wen, J., Gong, L., et al. (2017) Thrombospondin-1 Promotes Cell Migration, Invasion and Lung Metastasis of Osteosarcoma through FAK Dependent Pathway. Oncotarget, 8, 75881-75892.
https://doi.org/10.18632/oncotarget.17427
|
[26]
|
Bartucci, M., Dattilo, R., Moriconi, C., et al. (2015) TAZ Is Required for Metastatic Activity and Chemoresistance of Breast Cancer Stem Cells. Oncogene, 34, 681-690. https://doi.org/10.1038/onc.2014.5
|
[27]
|
Li, Y. and Jones, S. (2012) Drug Repositioning for Personalized Medicine. Genome Medicine, 4, 27.
https://doi.org/10.1186/gm326
|
[28]
|
Yang, C., Lee, W., Cheng, H., et al. (2019) The Antipsychotic Chlorpromazine Suppresses YAP Signaling, Stemness Properties, and Drug Resistance in Breast Cancer Cells. Chemico-Biological Interactions, 302, 28-35.
https://doi.org/10.1016/j.cbi.2019.01.033
|
[29]
|
蒋玉林, 刘一锋, 张志乾, 等. 维替泊芬通过下调Yes相关蛋白表达抑制MDA-MB-231乳腺癌细胞增殖及侵袭和迁移[J]. 细胞与分子免疫学杂志, 2017, 33(9): 1223-1227.
|
[30]
|
Liu, J., Li, J., Chen, H., et al. (2020) Metformin Suppresses Proliferation and Invasion of Drug-Resistant Breast Cancer Cells by Activation of the Hippo Pathway. Journal of Cellular and Molecular Medicine, 24, 5786-5796.
https://doi.org/10.1111/jcmm.15241
|
[31]
|
Zhao, Y., Khanal, P., Savage, P., et al. (2014) YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway. Cancer Research, 74, 4493-4503.
https://doi.org/10.1158/0008-5472.CAN-13-2712
|
[32]
|
Lai, D., Ho, K., Hao, Y., et al. (2011) Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets Cyr61 and CTGF. Cancer Research, 71, 2728-2738.
https://doi.org/10.1158/0008-5472.CAN-10-2711
|
[33]
|
Yuan, J., Ding, N. and Xiao, Z. (2020) The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients. Frontiers in Pharmacology, 11, Article ID: 537265. https://doi.org/10.3389/fphar.2020.537265
|
[34]
|
Qin, X., Lv, X., Li, P., et al. (2020) Matrix Stiffness Modulates ILK-Mediated YAP Activation to Control the Drug Resistance of Breast Cancer Cells. BBA Molecular Basis of Disease, 1866, Article ID: 165625.
https://doi.org/10.1016/j.bbadis.2019.165625
|
[35]
|
Lin, C., Pelissier, F., Zhang, H., et al. (2015) Microenvironment Rigidity Modulates Responses to the HER2 Receptor Tyrosine Kinase Inhibitor Lapatinib via YAP and TAZ Transcription Factors. Molecular Biology of the Cell, 26, 3946-3953. https://doi.org/10.1091/mbc.E15-07-0456
|
[36]
|
Oku, Y., Nishiya, N., Shito, T., et al. (2015) Small Molecules Inhibiting the Nuclear Localization of YAP/TAZ for Chemotherapeutics and Chemosensitizers against Breast Cancers. FEBS Open Bio, 5, 542-549.
https://doi.org/10.1016/j.fob.2015.06.007
|